Literature DB >> 9691100

Mobilization of potent plasma bactericidal activity during systemic bacterial challenge. Role of group IIA phospholipase A2.

Y Weinrauch1, C Abad, N S Liang, S F Lowry, J Weiss.   

Abstract

Extracellular mobilization of Group IIA 14-kD phospholipase A2 (PLA2) in glycogen-induced rabbit inflammatory peritoneal exudates is responsible for the potent bactericidal activity of the inflammatory fluid toward Staphylococcus aureus (1996. J. Clin. Invest. 97:250-257). Because similar levels of PLA2 are induced in plasma during systemic inflammation, we have tested whether this gives rise to plasma bactericidal activity not present in resting animals. Baboons were injected intravenously (i.v.) with a lethal dose of Escherichia coli and plasma or serum was collected before and at hourly intervals after injection. After infusion of bacteria, PLA2 levels in plasma and serum rose > 100-fold over 24 h to approximately 1 microg PLA2/ml. Serum collected at 24 h possessed potent bactericidal activity toward S. aureus, Streptococcus pyogenes, and encapsulated E. coli not exhibited by serum collected from unchallenged animals. Bactericidal activity toward S. aureus and S. pyogenes was nearly completely blocked by a monoclonal antibody to human Group IIA PLA2 and addition of purified human Group IIA PLA2 to prechallenge serum conferred potent antistaphylococcal and antistreptococcal activity equal to that of the 24 h post-challenge serum. PLA2-dependent bactericidal activity was enhanced approximately 10x by factor(s) present constitutively in serum or plasma. Bactericidal activity toward encapsulated E. coli was accompanied by extensive bacterial phospholipid degradation mediated, at least in part, by the mobilized Group IIA PLA2 but depended on the action of other bactericidal factors in the 24-h serum. These findings further demonstrate the contribution of Group IIA PLA2 to the antibacterial potency of biological fluids and suggest that mobilization of this enzyme during inflammation may play an important role in host defense against invading bacteria.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9691100      PMCID: PMC508924          DOI: 10.1172/JCI3121

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Utilization of labeled Escherichia coli as phospholipase substrate.

Authors:  P Elsbach; J Weiss
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

Review 2.  Bacteriophage-mediated generalized transduction in Escherichia coli and Salmonella typhimurium.

Authors:  N L Sternberg; R Maurer
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

3.  Human group II phospholipase A2. Characterization of monoclonal antibodies and immunochemical quantitation of the protein in synovial fluid.

Authors:  C R Stoner; L M Reik; M Donohue; W Levin; R M Crowl
Journal:  J Immunol Methods       Date:  1991-12-15       Impact factor: 2.303

Review 4.  A reassessment of the low molecular weight phospholipase A2 gene family in mammals.

Authors:  J A Tischfield
Journal:  J Biol Chem       Date:  1997-07-11       Impact factor: 5.157

5.  Effects of human and rabbit serum on viability, permeability, and envelope lipids of Serratia marcescens.

Authors:  S Beckerdite-Quagliata; M Simberkoff; P Elsbach
Journal:  Infect Immun       Date:  1975-04       Impact factor: 3.441

Review 6.  Mammalian non-pancreatic phospholipases A2.

Authors:  I Kudo; M Murakami; S Hara; K Inoue
Journal:  Biochim Biophys Acta       Date:  1993-11-03

7.  Bacterial phospholipid hydrolysis enhances the destruction of Escherichia coli ingested by rabbit neutrophils. Role of cellular and extracellular phospholipases.

Authors:  G C Wright; J Weiss; K S Kim; H Verheij; P Elsbach
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

8.  Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response.

Authors:  R M Crowl; T J Stoller; R R Conroy; C R Stoner
Journal:  J Biol Chem       Date:  1991-02-05       Impact factor: 5.157

9.  Synovial-type (group II) phospholipase A2 human seminal plasma.

Authors:  T J Nevalainen; K M Meri; M Niemi
Journal:  Andrologia       Date:  1993 Nov-Dec       Impact factor: 2.775

10.  Conversion of pig pancreas phospholipase A2 by protein engineering into enzyme active against Escherichia coli treated with the bactericidal/permeability-increasing protein.

Authors:  J Weiss; G Wright; A C Bekkers; C J van den Bergh; H M Verheij
Journal:  J Biol Chem       Date:  1991-03-05       Impact factor: 5.157

View more
  43 in total

Review 1.  How methicillin-resistant Staphylococcus aureus evade neutrophil killing.

Authors:  Mallary Greenlee-Wacker; Frank R DeLeo; William M Nauseef
Journal:  Curr Opin Hematol       Date:  2015-01       Impact factor: 3.284

2.  The molecular basis of phosphatidylcholine preference of human group-V phospholipase A2.

Authors:  K P Kim; S K Han; M Hong; W Cho
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

3.  Antibacterial action of extracellular mammalian group IIA phospholipase A2 against grossly clumped Staphylococcus aureus.

Authors:  M E Dominiecki; J Weiss
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 4.  Mammalian antibiotic peptides.

Authors:  P Síma; I Trebichavský; K Sigler
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

Review 5.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

6.  In vitro anti-Plasmodium falciparum properties of the full set of human secreted phospholipases A2.

Authors:  Carole Guillaume; Christine Payré; Ikram Jemel; Louise Jeammet; Sofiane Bezzine; Gajendra S Naika; James Bollinger; Philippe Grellier; Michael H Gelb; Joseph Schrével; Gérard Lambeau; Christiane Deregnaucourt
Journal:  Infect Immun       Date:  2015-03-30       Impact factor: 3.441

7.  Time-Restricted Feeding Alters the Innate Immune Response to Bacterial Endotoxin.

Authors:  Yasmine M Cissé; Jeremy C Borniger; Elise Lemanski; William H Walker; Randy J Nelson
Journal:  J Immunol       Date:  2017-12-04       Impact factor: 5.422

8.  IL-25 improves luminal innate immunity and barrier function during parenteral nutrition.

Authors:  Aaron F Heneghan; Joseph F Pierre; Ankush Gosain; Kenneth A Kudsk
Journal:  Ann Surg       Date:  2014-02       Impact factor: 12.969

9.  Wall teichoic acid deficiency in Staphylococcus aureus confers selective resistance to mammalian group IIA phospholipase A(2) and human beta-defensin 3.

Authors:  Tomaz Koprivnjak; Christopher Weidenmaier; Andreas Peschel; Jerrold P Weiss
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

10.  Parenteral nutrition increases susceptibility of ileum to invasion by E coli.

Authors:  Joseph F Pierre; Aaron F Heneghan; Jennifer M Meudt; Michael P Shea; Christian G Krueger; Jess D Reed; Kenneth A Kudsk; Dhanansayan Shanmuganayagam
Journal:  J Surg Res       Date:  2013-02-24       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.